2
Sep
2020
Beyond AAV: AVROBIO and Orchard Take Ex Vivo Approach to Gene Therapy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Sep
2020
Mood Disorder R&D, Lacking Innovation, Turns to Psychedelics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Aug
2020
The Data Are Telling Us to Prepare for a Difficult Fall
I could not resist using the above, peerless comic strip from Stephan Pastis. Indeed, the two “plagues” are not just co-existing, but they are mutually reinforcing each other and making things worse. We should take the “great wise ass on the hill” seriously and invest in science and (investigative, high quality) journalism. About two months ago, I wrote here about... Read More
28
Aug
2020
A Swing and a Miss from the CDC
Please help me understand the value of OUR Centers for Disease Control and Prevention in 2020. It’s baseball season — sort of. We have been waiting and waiting for the CDC to step up to home plate. The bases have been loaded for 7 months, and their fans have been waiting. The CDC is supposed to be our national cleanup... Read More
27
Aug
2020
Convalescent Plasma: Look Before You Leap
In the last few days I have been wondering how Michael Joyner and Arturo Casadevall have been feeling. Joyner and Casadevall are the first and senior authors, respectively, of the report, “Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three Month Experience,” posted on Medrxiv on August 12. The preprint server allows researchers to make their... Read More
26
Aug
2020
An Underappreciated Aspect of Power: Listening
As the summer draws to a close, I thought TR readers might enjoy a final August distraction. I’ve always been an avid reader, and lately, I’ve found myself increasingly drawn to the history and science of American politics. On the history front, and inspired by Stanford professor Jeffrey Pfeffer (an expert on power and leadership), I’ve started Robert Caro’s famously... Read More
24
Aug
2020
Insurance Reform, Not Executive Orders, Is the Best Tool to Protect U.S. Patients and U.S. Pharmaceutical Innovation
With today’s Aug. 24 deadline looming, it’s important to explain how President Trump’s “most favored nations” executive order to purportedly lower drug prices would actually backfire, and hurt patients both at home and abroad. The order, which ties prices for certain drugs paid for by Medicare to the lowest prices paid in other countries, including Canada and much of Europe,... Read More
20
Aug
2020
Spiritual Renewal in the North Cascades, and Facing Homelessness
All of us need some time and space for spiritual renewal. Especially in a year like 2020. Mountain climbing does it for me. Last weekend, I was fortunate to get out to Mt. Shuksan in the remote North Cascades of Washington. It was a gorgeous climb, led by my friends and partners at Alpine Ascents International. The climb was a... Read More
18
Aug
2020
Antibiotic Resistance Looms Large in Pandemic; CRISPR Phages Show Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Aug
2020
A Microbiome Turnaround, Novavax Gears Up, & Moderna Commits to 100m Doses
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Aug
2020
From Rio to Rome: Rosana Kapeller on The Long Run
Today’s guest on The Long Run is Rosana Kapeller. She’s the president and CEO of Cambridge, Mass.-based ROME Therapeutics. ROME aims to discover and develop drugs based on emerging science in what is sometimes called the “repeatome.” These are long repeat stretches of DNA that scientists until recently knew very little about, and still have a lot to learn about... Read More
11
Aug
2020
SpringWorks Faces Readout for Gamma Secretase Inhibitor; Eyes BCMA Combo for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2020
GSK’s BCMA Antibody Gets OK, Biogen Teams With Denali & A Telemedicine Megadeal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2020
COVID-19 Is Driving a Shift in How We Value Diagnostic Tests
There are very few things many of us can say with 100 percent certainty. But after three decades of experience in molecular diagnostics and the life science industry, I can say this: never before has the healthcare profession, and even the American public, been so laser-focused on diagnostics. For all the tragedy it has caused, the COVID-19 pandemic has shone... Read More
5
Aug
2020
Generation Bio Blazes New Trail in Gene Therapy with Non-Viral Approach
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2020
Versant Ventures Wagers $35M on Cytokine Engineering with Bright Peak
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2020
Akili Interactive Delivers Prescription Level Treatment via Video Games
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Aug
2020
Ohana Biosciences and Sperm Biology: The Other Half of the Fertility Equation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Jul
2020
Closing Medicine’s Feedback Gap: Can Tech Help Integrate Clinical Care and Clinical Research?
Medicine is plagued by a feedback gap, or perhaps more accurately, a feedback paradox. On the one hand, clinicians are bombarded by feedback. Every day, there are a slew of process and billing metrics to review, providing an accounting of the volume of patients seen, and the intensity of each visit. How thorough was the exam? What procedures may have... Read More
30
Jul
2020
Jill Hagenkord’s Rags To Riches Story Reminds Us Why We Still Admire Entrepreneurs
Entrepreneurial stories, often told through the narrative framework of the hero’s journey, are by now well past the point of cliché. Yet, it’s important, perhaps even instructive, to remind ourselves every now and again about the exceptional, transformative power of entrepreneurship, the can-do thinking it motivates, and the remarkable progress it can propel. This potential emerged as a central theme... Read More